A review of human vaccine research and development: malaria.
about
Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyondPlatform for Plasmodium vivax vaccine discovery and developmentCharacterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparumProtective properties and surface localization of Plasmodium falciparum enolaseVirosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & childrenThe dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in TanzaniaPhase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malariaWhat should vaccine developers ask? Simulation of the effectiveness of malaria vaccinesSafety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.A comparative proteomic analysis of the simple amino acid repeat distributions in Plasmodia reveals lineage specific amino acid selection.Construction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9.A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.Expanding the Antimalarial Drug Arsenal-Now, But How?Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytesEfficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis.Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques.Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine.Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.Towards an effective malaria vaccine.Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine candidate induce antibody-dependent respiratory burst in human neutrophilsInduction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations.Experience and challenges from clinical trials with malaria vaccines in AfricaAddition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels.Use of viral vectors for the development of vaccines.Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.Malaria - an overview.Various carrier system(s)- mediated genetic vaccination strategies against malaria.Malaria vaccines: a toy for travelers or a tool for eradication?Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in MaliApplication of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.
P2860
Q20905953-89D48C9D-B4E0-40AE-871A-347D3244B04FQ27021891-11DE6AF1-B354-41A6-BE7F-BDF295F3DC2EQ27972927-0C0217E6-FD95-40E4-90E2-D41E2A7AD4C6Q27973862-0133F85B-6BDB-4D88-B1A7-A1802DFCE74DQ28742277-55CF25B9-C497-43C1-84F7-701412B733CCQ28744581-A39CD8DD-4F3F-4C0F-88B1-CFC9BA782A55Q33319552-10EC6EAA-8307-40B7-AFA4-B305AAD8EF4DQ33359552-0A911079-A8B3-4D19-9CB5-AD93F5F9A42EQ33368617-33140D84-1834-4541-9571-AD5C5A868E73Q33394245-C7F5FC14-13F5-497C-924F-7599B7064093Q33481643-9726CF12-489C-488B-AD1F-53258F375C5CQ33499694-8F9A8112-65C6-41B6-AE4F-31C1426D26ECQ33512921-F6EF9085-12CC-49F9-B913-315CC8CED476Q33588543-CDCA6F00-F8B5-49DA-B7B8-B0D9D227D9BFQ33598040-32735D51-4362-4644-ADB7-D5C736A4CB10Q33892507-A2635193-2E04-46E3-9FED-F5B93FB92066Q33916111-84F61094-9DA2-469F-9C72-0661EFC22766Q34367020-9E411425-B0AB-4CA9-83C6-6B9CC86E7A9DQ34548672-6F0ADFC4-66C4-454C-8A11-D2760B2D5606Q34615872-ADE6D85C-F2C0-4669-A614-A17BD25C92F8Q35079044-2E181716-C605-49C6-ACD4-CCF0A26213B3Q35138725-3073D6D2-F944-4D31-8A36-B0DC31CEC641Q35742175-E747C963-553C-4FE7-816B-ADB5030B0740Q36121709-05535EE3-AD79-441E-93A2-26CFF9D86A2AQ36169093-1D0A750F-9B6B-4956-90FB-3C9ABAA5E063Q36285998-1F4129DE-8086-4BCF-B037-E8C6D1633253Q36398138-DD195B96-55DC-4E4E-AE71-5B0E4672C755Q36690983-5D4E026B-2EBF-469D-97C9-5C5880D72662Q36718066-B4E07F23-2116-43FA-90F7-D1C322461089Q36729948-1F6ED387-4806-444B-9BA7-663D96E20113Q36780156-55D6C3C4-8CD3-4F1A-9676-A37F5BDEA0BAQ36795388-9B558BAD-CCF5-4CE2-B957-753E6F17DC1BQ36933774-7ECA10F4-F366-4BA4-8A32-B0EF93289461Q37150329-8D72B598-96E4-43A0-841D-1F1940427679Q37194780-A992D964-1A88-4289-B183-34762521292AQ37256085-36E6483A-85EB-4341-8CF0-BB6B63CABD28Q37267850-7602DF65-C9E2-4E8E-9AD6-73A371A2D07DQ37278622-F242CAEC-ABFE-47E4-982A-2378A84007D5Q37762275-BE60BDE5-39E6-443F-AAB2-5FBAC2E78E76Q37771945-020FE1C6-8D10-4179-9940-AB088DD70738
P2860
A review of human vaccine research and development: malaria.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A review of human vaccine research and development: malaria.
@ast
A review of human vaccine research and development: malaria.
@en
type
label
A review of human vaccine research and development: malaria.
@ast
A review of human vaccine research and development: malaria.
@en
prefLabel
A review of human vaccine research and development: malaria.
@ast
A review of human vaccine research and development: malaria.
@en
P2093
P1433
P1476
A review of human vaccine research and development: malaria.
@en
P2093
Marc P Girard
Martin Friede
Zarifah H Reed
P304
P356
10.1016/J.VACCINE.2006.09.074
P407
P577
2006-10-05T00:00:00Z